Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice

Biochimica et Biophysica Acta - General Subjects

Volumn 1524, Issue 2-3, 2000, Pages 258-265

  Kawakami, Shigeru ^a   Wong, Joseph ^b   Sato, Ayumi ^a   Hattori, Yoshiyuki ^a   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Asialoglycoprotein receptor; Drug delivery system; Fucose receptor; Glycosylated liposome; Mannose receptor; Targeting

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; CHOLESTEN 5 YLOXY N [4 [(1 IMINO 2 BETA DEXTRO THIOFUCOSYLETHYL)AMINO]ALKYL]FORMAMIDE; CHOLESTEN 5 YLOXY N [4 [(1 IMINO 2 BETA DEXTRO THIOGALACTOSYLETHYL)AMINO]ALKYL]FORMAMIDE; CHOLESTEN 5 YLOXY N [4 [(1 IMINO 2 BETA DEXTRO THIOMANNOSYLETHYL)AMINO]ALKYL]FORMAMIDE; CHOLESTEROL; CHOLESTEROL DERIVATIVE; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG RECEPTOR; FUCOSE RECEPTOR; GLYCOSYLATED PROTEIN; LIPOSOME; MANNOSE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SYNTHESIS; DRUG UPTAKE; FUCOSYLATION; GLYCOSYLATION; LIVER PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; FUCOSE; GALACTOSE; GENE THERAPY; GLYCOLIPIDS; GLYCOSYLATION; INJECTIONS, INTRAVENOUS; KUPFFER CELLS; LIPOSOMES; LIVER; MANNOSE; MICE; PARTICLE SIZE; TIME FACTORS; TISSUE DISTRIBUTION; TRITIUM;

ANIMALIA;

EID: 0034672561     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(00)00163-X     Document Type: Article

References (37)

1. Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion
2. Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties
3. Mannosylated superoxide dismutase inhibits hepatic reperfusion injury in rats
4. Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by extent of galactosylation
5. Targeted delivery and improved therapeutic potential of catalase by chemical modification: Combination with superoxide dismutase derivatives
6. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution
7. Development of a hepatocyte-specific prostaglandin E1 polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice
8. Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery
9. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules
10. Specific targeting of the antiviral drug 5-iodo 2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine
11. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor
12. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: Pharmacokinetics in DBA2 mice
13. Anticancer therapy using glucuronate modified long-circulating liposomes
14. Pegylated-liposomal doxorubicin (DOXIL) in the treatment of AIDS-related Kaposi's sarcoma
15. Ligand-targeted liposomes
16. Therapeutic opportunities for targeted liposomal drug delivery
17. Increased liver uptake and improved targeting efficacy by labeling with asialofetuin in rodents
18. Preparation of asialofetuin-labeled liposomes with encapsulated human interferon-gamma and their uptake by isolated rat hepatocytes
19. Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo
20. The effects of a water soluble tris-galactoside terminated cholesterol derivative on the in vivo fate of small unilammelar vesicles in rat
21. Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s
22. Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor
23. 1 to hepatocytes using galactosylated liposomes
24. Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs
25. Liposomal sustained-release delivery systems for intravenous injection. I. Physicochemical and biological properties of newly synthesized lipophilic derivatives of mitomycin C
26. Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes
27. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes
28. 2-Imino-2-methoxyethyl-1-thioglycosides: New reagents for attaching sugars to proteins
29. In vivo behavior of liposomes modified with a novel galactosyllipid derivative
30. Influence of cholesterol on the association of plasma proteins with liposomes
31. Physiologically based pharmacokinetic modeling: Principles and applications
32. The distribution and localization of the fucose-binding lectin in rat tissues and the identification of a high affinity form of the mannose/N-acetylglucosamine-binding lectin in rat liver
33. Characterization of the interaction of galactose-exposing particles with rat Kupffer cells
34. Mannose receptor mediated uptake of antigens strongly enhances HLA-class II restricted antigen presentation by cultured dendric cells
35. Mannose-mediated targeted immunoadjuvant action of liposomes
36. Oligomannose-coated liposomes as an adjuvant for the induction of cell-mediated immunity
37. Liposome oligomannose coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes